These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 20837956)

  • 1. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
    Midgley RS; McConkey CC; Johnstone EC; Dunn JA; Smith JL; Grumett SA; Julier P; Iveson C; Yanagisawa Y; Warren B; Langman MJ; Kerr DJ
    J Clin Oncol; 2010 Oct; 28(30):4575-80. PubMed ID: 20837956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VICTOR spoiled?
    Goldberg RM; Bertagnolli MM
    J Clin Oncol; 2010 Oct; 28(30):4546-8. PubMed ID: 20837951
    [No Abstract]   [Full Text] [Related]  

  • 3. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
    Kerr DJ; Dunn JA; Langman MJ; Smith JL; Midgley RS; Stanley A; Stokes JC; Julier P; Iveson C; Duvvuri R; McConkey CC;
    N Engl J Med; 2007 Jul; 357(4):360-9. PubMed ID: 17652651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
    Domingo E; Church DN; Sieber O; Ramamoorthy R; Yanagisawa Y; Johnstone E; Davidson B; Kerr DJ; Tomlinson IP; Midgley R
    J Clin Oncol; 2013 Dec; 31(34):4297-305. PubMed ID: 24062397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
    Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
    Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
    Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA;
    N Engl J Med; 2005 Mar; 352(11):1092-102. PubMed ID: 15713943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
    Lanas A; Baron JA; Sandler RS; Horgan K; Bolognese J; Oxenius B; Quan H; Watson D; Cook TJ; Schoen R; Burke C; Loftus S; Niv Y; Ridell R; Morton D; Bresalier R
    Gastroenterology; 2007 Feb; 132(2):490-7. PubMed ID: 17258718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study.
    Becerra CR; Frenkel EP; Ashfaq R; Gaynor RB
    Int J Cancer; 2003 Jul; 105(6):868-72. PubMed ID: 12767075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does perioperative administration of rofecoxib improve analgesia after spine, breast and orthopaedic surgery?
    Riest G; Peters J; Weiss M; Pospiech J; Hoffmann O; Neuhäuser M; Beiderlinden M; Eikermann M
    Eur J Anaesthesiol; 2006 Mar; 23(3):219-26. PubMed ID: 16430794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, placebo-controlled, single-dose studies.
    Daniels SE; Desjardins PJ; Bird SR; Smugar SS; Tershakovec AM
    Clin Ther; 2006 Jul; 28(7):1022-34. PubMed ID: 16990080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
    Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM
    Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases.
    Fenwick SW; Toogood GJ; Lodge JP; Hull MA
    Gastroenterology; 2003 Sep; 125(3):716-29. PubMed ID: 12949718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial.
    Baron JA; Sandler RS; Bresalier RS; Lanas A; Morton DG; Riddell R; Iverson ER; Demets DL
    Lancet; 2008 Nov; 372(9651):1756-64. PubMed ID: 18922570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
    Ohrling K; Edler D; Hallström M; Ragnhammar P
    Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
    Hsiao FY; Tsai YW; Huang WF
    Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory?
    Lynch PM
    Gastroenterology; 2006 Dec; 131(6):2003-5. PubMed ID: 17188962
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
    Meyerhardt JA; Shi Q; Fuchs CS; Meyer J; Niedzwiecki D; Zemla T; Kumthekar P; Guthrie KA; Couture F; Kuebler P; Bendell JC; Kumar P; Lewis D; Tan B; Bertagnolli M; Grothey A; Hochster HS; Goldberg RM; Venook A; Blanke C; O'Reilly EM; Shields AF
    JAMA; 2021 Apr; 325(13):1277-1286. PubMed ID: 33821899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.
    Reiff A; Lovell DJ; Adelsberg JV; Kiss MH; Goodman S; Zavaler MF; Chen PY; Bolognese JA; Cavanaugh P; Reicin AS; Giannini EH
    J Rheumatol; 2006 May; 33(5):985-95. PubMed ID: 16583464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.